| Original language | English |
|---|---|
| Pages (from-to) | 199-199 |
| Number of pages | 1 |
| Journal | Medical Journal of Australia |
| Volume | 182 |
| Issue number | 4 |
| Publication status | Published - 21 Feb 2005 |
Cite this
Langton, P., Hankey, G., & Eikelboom, J. (2005). Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. Medical Journal of Australia, 182(4), 199-199.
@article{9f07b00335074b1fb0d330d996f909ae,
title = "Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions",
keywords = "RANDOMIZED CONTROLLED-TRIALS, ENDOTHELIAL FUNCTION, OSTEOARTHRITIS, INHIBITION, VALDECOXIB, EFFICACY, DISEASE",
author = "P Langton and G Hankey and J Eikelboom",
year = "2005",
month = "2",
day = "21",
language = "English",
volume = "182",
pages = "199--199",
journal = "Medical Journal Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "4",
}
Langton, P, Hankey, G & Eikelboom, J 2005, 'Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions' Medical Journal of Australia, vol. 182, no. 4, pp. 199-199.
Cardiovascular safety of rofecoxib (Vioxx) : lessons learned and unanswered questions. / Langton, P; Hankey, G; Eikelboom, J.
In: Medical Journal of Australia, Vol. 182, No. 4, 21.02.2005, p. 199-199.Research output: Contribution to journal › Letter
TY - JOUR
T1 - Cardiovascular safety of rofecoxib (Vioxx)
T2 - lessons learned and unanswered questions
AU - Langton, P
AU - Hankey, G
AU - Eikelboom, J
PY - 2005/2/21
Y1 - 2005/2/21
KW - RANDOMIZED CONTROLLED-TRIALS
KW - ENDOTHELIAL FUNCTION
KW - OSTEOARTHRITIS
KW - INHIBITION
KW - VALDECOXIB
KW - EFFICACY
KW - DISEASE
M3 - Letter
VL - 182
SP - 199
EP - 199
JO - Medical Journal Australia
JF - Medical Journal Australia
SN - 0025-729X
IS - 4
ER -
Langton P, Hankey G, Eikelboom J. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. Medical Journal of Australia. 2005 Feb 21;182(4):199-199.